Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
The collaboration will harness Thermo Fisher's technologies, instrumentation and information translation systems to enable Mainz Biomed to develop proprietary assays for its mRNA-based next-generation colorectal cancer screening tests.Mainz Biomed N.V. (NASDAQ:MYNZ) announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer.
Mainz Biomed N.V.（納斯達克：MYNZ）宣佈進行1比40的反向股票拆分，生效日期爲12月3日。該公司專注於癌症的早期檢測。
Last month, Mainz Biomed reported a collaborative agreement with Thermo Fisher Scientific Inc. (NYSE:TMO) through its subsidiary Life Technologies Corporation.
上個月，Mainz Biomed與賽默飛世爾科技公司（紐交所：TMO）通過其子公司生命科技公司達成了合作協議。
The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed's Next Generation colorectal cancer screening product.
這一合作協議將使Mainz Biomed和賽默飛世爾共同開發並可能商業化Mainz Biomed的下一代結直腸癌篩查產品。
The collaboration will harness Thermo Fisher's technologies, instrumentation and information translation systems to enable Mainz Biomed to develop proprietary assays for its mRNA-based next-generation colorectal cancer screening tests.
該合作將藉助賽默飛世爾的技術、儀器和信息轉化系統，使Mainz Biomed能夠爲其基於mRNA的下一代結直腸癌篩查測試開發專有測定方法。
Mainz Biomed's flagship non-invasive test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.
Mainz Biomed的旗艦非侵入性測試瞄準結直腸癌的早期檢測，重點關注癌前病變，特別是愛文思控股。
The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed's laboratories in Mainz, Germany.
合作將藉助邁因茨生物醫學在德國邁因茨實驗室開發的測試解決方案的綜合能力。
Guido Baechler, CEO of Mainz Biomed, said: "This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas."
Mainz Biomed的首席執行官Guido Baechler表示：「與賽默飛世爾的這一合作將對我們的目標至關重要，即推出一種具有高效腺瘤檢測能力的家庭採樣結直腸篩查工具。」
In October, Mainz Biomed reported a 4% increase in revenue and a 32% decrease in operational losses for the first half of 2024. These decreases result from the company's efforts to reduce costs during the first half of the year.
在十月份，Mainz Biomed報告稱2024年上半年營業收入增長了4%，運營虧損減少了32%。這些減少是由於公司在上半年努力降低成本所致。
The company announced significant improvements to its ColoAlert product, which is available across Europe and in select international markets.
該公司宣佈對其ColoAlert產品進行了重大改進，該產品在整個歐洲及部分國際市場上可用。
The company says that the new proprietary buffer used in ColoAlert significantly reduces the necessity for additional sample submissions, thereby decreasing how long it takes patients to obtain their results.
該公司表示，ColoAlert中使用的新專有緩衝液顯著減少了額外樣本提交的必要性，從而縮短了患者獲取結果的時間。
This enhancement enabled ColoAlert to achieve the industry's lowest retesting rates, ensuring that screening outcomes are delivered within two to three days of arrival at the laboratory.
這一增強使ColoAlert達到了行業板塊最低的重測率，確保篩查結果在到達實驗室後兩到三天內交付。
Price Action: MYNZ stock is down 13.09% at $6.93 at publication Tuesday.
價格動態：MYNZ股票在週二發佈時下跌了13.09%，報6.93美元。
- BlackRock Makes $12 Billion Power Move – Agrees To Acquire HPS To Bolster Private Credit Offerings
- 貝萊德（BlackRock）120億美元重磅動作 - 同意收購HPS以增強私人信貸業務。
Photo: Shutterstock
Photo: shutterstock
譯文內容由第三人軟體翻譯。
